Ticagrelor Versus High-dose Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After PCI

Phase 3 Withdrawn Nanjing First Hospital, Nanjing Medical University

RandomizedParallel-groupSingle-blindPrevention

Summary

To determine the safety and efficacy of Ticagrelor versus Clopidogrel for the reduction of adverse cardiovascular outcomes in patients with high platelet reactivity on clopidogrel after successful implantation of coronary drug-eluting stents.

Timeline

Start: 2017-06-20
Primary completion: 2021-05-30
Completion: 2021-05-30

Outcome

Outcome not reported

Stopped (Enrollment): “Competitive studies were conducted at the same time, and enrollment was suspended.”

Publications

Background Zhang JJ, Gao XF, Ge Z, Tian NL, Liu ZZ, Lin S, Ye F, Chen SL. High platelet reactivity affects the clinical outcomes of patients undergoing percutaneous coronary intervention. BMC Cardiovasc Disord. 2016 Nov 29;16(1):240. doi: 10.1186/s12872-016-0394-0.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Clopidogrel	Small molecule	150 mg	—
Subject	Ticagrelor	Small molecule	180 mg	—